The search query “99v orange pill” (or “99 V” / “V 99”) typically refers to a visual misreading or partial reading of the distinctive “V” logo debossed tablets manufactured by Vintage Pharmaceuticals / Qualitest Pharmaceuticals:
- Oxycodone Hydrochloride 10 mg (Primary Match – Imprint:
Von one side,49 93on reverse): A round, pink-to-light-orange/peach tablet where the “49 93” imprint is frequently misread as “99” or “99 V”. - Related “V” Logo Orange Round Formulations: Other orange round tablets bearing the signature Qualitest “V” include Cyclobenzaprine Hydrochloride 5 mg (marked
V 2631) and Allopurinol 300 mg (marked2084 V).
Below is the detailed clinical and pharmacological profile for the primary Schedule II controlled substance match, Oxycodone Hydrochloride 10 mg (V 49 93).
Pill Identification
Attribute – Specification
- Active Ingredient – Oxycodone Hydrochloride, USP (10 mg)
- Imprint – V on one side; 49 93 across a score line on the reverse
- Color & Shape – Pink to light orange/peach, round, scored tablet
- Diameter – Approximately 6 mm to 7 mm
- Manufacturer – Qualitest Pharmaceuticals / Vintage Pharmaceuticals (Endo)
- Drug Class – Pure Opioid Agonist / Narcotic Analgesic
- Controlled Substance Schedule – DEA Schedule II (C-II)
Mechanism of Action
Oxycodone is a semi-synthetic, pure opioid agonist derived from the thebaine alkaloid:
- Opioid Receptor Binding: Oxycodone selectively binds to and activates (mu)-opioid receptors in the central nervous system (CNS), spinal cord, and peripheral tissues. It also has a minor affinity for kappa and delta receptors.
- G-Protein Coupled Inhibition: Stimulation of the receptor inhibits intracellular adenylyl cyclase, reducing cyclic adenosine monophosphate (cAMP) levels.
- Hyperpolarization & Neurotransmitter Blockade: This closes presynaptic voltage-gated N-type calcium channels and opens postsynaptic inwardly rectifying potassium channels, hyperpolarizing neuronal membranes. This blocks the release of excitatory neurotransmitters (substance P, glutamate, and calcitonin gene-related peptide), inhibiting ascending nociceptive pain pathways and altering the emotional perception of pain.
Indications and Clinical Uses
- Moderate to Severe Acute Pain: Indicated for the management of acute pain severe enough to require an opioid analgesic (e.g., major surgery, severe traumatic injury, acute orthopedic trauma) when alternative non-opioid treatments (NSAIDs, acetaminophen) are inadequate or contraindicated.
- Severe Breakthrough Pain: Used in opioid-tolerant patients experiencing breakthrough pain in chronic conditions (such as advanced cancer) under specialized pain management protocols.
Dosage and Administration
- Prescribing guidelines require initiating therapy at the lowest effective dose for the shortest duration necessary.
- Opioid-Naïve Adult Starting Dose: Typically 5 mg to 10 mg orally every 4 to 6 hours as needed for pain.
- Dose Titration: Titrated individually based on the severity of pain, previous exposure to opioids, and patient tolerance.
- Administration: Swallow whole with a full glass of water. Can be taken with food or milk to minimize potential nausea.
- Hepatic and Renal Impairment: Because oxycodone is extensively metabolized by the liver and excreted by the kidneys, starting doses should be reduced (often by 50% to 67%) with extended dosing intervals.
- Discontinuation: If taken continuously for more than several days, the dose must be tapered gradually under medical supervision to avoid triggering acute opioid withdrawal syndrome.
Side Effects
Common Adverse Reactions:
- Central Nervous System: Somnolence/drowsiness, dizziness, sedation, lightheadedness, headache
- Gastrointestinal: Constipation (requires proactive fluid/fiber intake or stool softeners), nausea, vomiting, xerostomia (dry mouth)
- Dermatologic / Autonomic: Pruritus (itching), flushing, hyperhidrosis (excessive sweating)
Serious Adverse Reactions:
- Life-Threatening Respiratory Depression: Severe reduction in breathing rate/depth, hypoventilation, apnea, or respiratory arrest.
- Profound CNS Depression: Stupor, coma, profound lethargy.
- Cardiovascular Collapse: Severe hypotension, bradycardia, orthostatic syncope.
- Serotonin Syndrome: High risk when co-administered with serotonergic antidepressants; presents with tremor, clonus, hyperreflexia, hyperthermia, and confusion.
- Adrenal Insufficiency: Decreased cortisol production linked to long-term opioid therapy.
Key Drug Interactions
- Benzodiazepines & CNS Depressants: Co-administration with benzodiazepines, barbiturates, muscle relaxants, tranquilizers, or alcohol exponentially increases the risk of severe respiratory depression, coma, and fatal overdose.
- CYP3A4 Inhibitors and Inducers:
- CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) increase oxycodone plasma concentrations, raising the risk of fatal overdose.
- CYP3A4 Inducers (e.g., rifampin, carbamazepine, St. John’s wort) lower plasma levels, decreasing pain relief and potentially precipitating withdrawal.
- CYP2D6 Inhibitors: Medications inhibiting CYP2D6 (e.g., fluoxetine, paroxetine) alter the metabolic conversion of oxycodone into its active metabolite, oxymorphone.
- MAO Inhibitors: Opioids should not be taken within 14 days of monoamine oxidase inhibitor (MAOI) therapy.
Boxed Warnings and Precautions
- Addiction, Abuse, and Misuse: Oxycodone carries a high potential for substance use disorder, physical dependence, misuse, and diversion.
- Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression can occur even at standard therapeutic doses, with peak vulnerability during initial therapy or dose escalation.
- Accidental Pediatric Ingestion: Accidental ingestion of a single 10 mg tablet by a child can result in fatal opioid poisoning.
- Neonatal Opioid Withdrawal Syndrome (NOWS): Chronic maternal use during pregnancy leads to life-threatening withdrawal in the neonate requiring specialized neonatal intensive care.
- Contraindications: Severe respiratory depression; acute or severe bronchial asthma in unmonitored settings; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to oxycodone.